Repligen Corporation (NASDAQ:RGEN), might not be a large cap stock, but it received a lot of attention from a substantial price movement on the NASDAQGS over the last few months, increasing to US$144 ...
When InvestingPro’s Fair Value model identified Repligen Corporation (NASDAQ:RGEN) as significantly overvalued on January 30, 2024, many investors were optimistic about the bioprocessing company’s ...
Repligen, a leading company in biological drug manufacturing, has seen significant growth with sales increasing from $141 million in FY17 to $802 million in FY22, largely due to their single-use ...
Repligen Corporation reported its second-quarter earnings for 2025, revealing a mixed financial performance. The company posted an earnings per share (EPS) of $0.37, slightly below the forecasted ...
According to Adhishthana principles, a stock typically breaks out of its Cakra pattern in Phase 9, which starts a strong upward move. This marks the beginning of the Himalayan Formation, a rally that ...
WALTHAM, Mass., Jan. 06, 2025 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced the commercial launch of ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results